StockWatch
·
Cement & Cement Products
Quarterly Result12 Nov 2026, 02:52 pm

Visaka Q2 FY27: PAT turns to ₹71 Cr on HCA windfall; core profit just ₹17 Cr

AI Summary

Visaka Industries' consolidated PAT swung to ₹71.30 Cr (EPS ₹8.25) in Q2 FY27 from a net loss of ₹8.72 Cr a year ago, on revenue of ₹399.24 Cr, up 22.8% YoY. But the headline is inflated by a ₹68.73 Cr pre-tax exceptional gain — the Supreme Court-upheld arbitral award against the Hyderabad Cricket Association (HCA) for a 2011 sponsorship-contract dispute dating to 2004, finally realised this quarter. Stripped of that one-off, consolidated core PBT was ₹17.10 Cr (adjusted PAT ~₹14.2 Cr) against a core pretax loss of ₹11.29 Cr a year ago — a genuine but modest underlying turnaround, not the ~₹80 Cr swing the reported numbers suggest. On a sequential basis PAT rose 35.3% QoQ, but that too is purely the exceptional item at work: core PBT actually fell from ₹70.62 Cr in Q1 FY27 to ₹17.10 Cr this quarter, a seasonal pattern as Q1 (April-June) is the pre-monsoon stocking peak for roofing and building products, which is why revenue also fell 32.3% QoQ from Q1's ₹590.07 Cr. Margins tell a more encouraging organic story: operating margin (OPM), which sits above the exceptional-item line and so is unaffected by the HCA gain, expanded to 9.40% from 3.61% a year ago — recovery from the commodity-cost and pricing pressure that drove last year's loss — even as it normalised down from Q1's seasonally elevated 15.48%. Standalone PAT came in at ₹66.35 Cr (EPS ₹7.68), about 7% below the consolidated figure; the gap is a ₹5 Cr provision for diminution in the holding company's investment in subsidiary Atum Life Private Limited, which is eliminated on consolidation — not a divergent underlying story. The company has no formal prior guidance or concall commentary on record to grade this print against, and no analyst consensus estimates for this specific quarter turned up in a search (results were declared same-day, November 12, 2026), so both vs-guidance and vs-street read as unknown rather than a miss or beat. Two board actions this quarter frame the medium-term picture rather than this print: a ₹175 Cr plant-expansion approval in August 2026, and the September 2026 appointment of Go India Advisors as IR agency, signalling a push for more investor visibility as the company builds capacity.

Key Highlights

  • Consolidated PAT ₹71.30 Cr (EPS ₹8.25) vs a net loss of ₹8.72 Cr in Q2 FY26 — but includes a ₹68.73 Cr pre-tax exceptional gain from the HCA arbitration award; ex-exceptional, core PBT was ₹17.10 Cr vs a core pretax loss of ₹11.29 Cr a year ago.
  • Revenue from operations ₹399.24 Cr, up 22.8% YoY but down 32.3% QoQ from Q1 FY27's seasonally strong ₹590.07 Cr (pre-monsoon stocking quarter for building products).
  • Operating margin (OPM) — unaffected by the exceptional item — expanded to 9.40% from 3.61% YoY, a genuine recovery, though down from Q1 FY27's seasonal 15.48% peak.
  • Standalone PAT ₹66.35 Cr (EPS ₹7.68) vs consolidated ₹71.30 Cr; the gap is a ₹5 Cr provision for diminution in the holding company's investment in subsidiary Atum Life, which nets out on consolidation.
  • Board approved a ₹175 Cr plant-capacity expansion in August 2026 and appointed Go India Advisors as IR agency in September 2026.
  • No prior formal guidance or concall commentary on record to benchmark this result against.